Literature DB >> 6183210

Isolation of hybridoma cell lines and characterization of monoclonal antibodies against cholera enterotoxin and its subunits.

M Robb, J C Nichols, S K Whoriskey, J R Murphy.   

Abstract

Hybridoma cell lines which produced monoclonal antibodies against cholera toxin were isolated. These cell lines were detected with an enzyme-linked immunosorbent assay screening procedure with purified cholera toxin or subunit A of cholera toxin. Seven cell lines were characterized with respect to their reactivity with cholera toxin subunits by Western blot analysis. Five clones produced antibodies which were directed against subunit A, and two clones produced antibodies which reacted with subunit B. These antibodies were also characterized by Western blot analysis for reactivity with the heat-labile enterotoxin produced by porcine and human enterotoxinogenic strains of Escherichia coli. Monoclonal antibodies which reacted with subunit A of cholera toxin also reacted with subunit A of both porcine and human heat-labile enterotoxins. In contrast, monoclonal antibodies to subunit B of cholera toxin did not react with subunit B of the heat-labile enterotoxin. Antibodies directed against subunit B neutralized the biological activity of cholera toxin in vitro in the S49 mouse lymphosarcoma assay. In contrast to polyclonal anti-subunit A antisera, monoclonal anti-subunit A from four of five clones had small but measurable neutralizing capacities in vitro.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6183210      PMCID: PMC347728          DOI: 10.1128/iai.38.1.267-272.1982

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  26 in total

1.  Simple method for purifying choleragenoid, the natural toxoid of Vibrio cholerae.

Authors:  J J Mekalanos; R J Collier; W R Romig
Journal:  Infect Immun       Date:  1977-06       Impact factor: 3.441

Review 2.  Mechanism of action of cholera toxin.

Authors:  D M Gill
Journal:  Adv Cyclic Nucleotide Res       Date:  1977

Review 3.  Field M: Intestinal secretion: effect of cyclic AMP and its role in cholera.

Authors: 
Journal:  N Engl J Med       Date:  1971-05-20       Impact factor: 91.245

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  The subunits of cholera toxin: structure, stoichiometry, and function.

Authors:  S van Heyningen
Journal:  J Infect Dis       Date:  1976-03       Impact factor: 5.226

6.  Dissociation and recombination of the subunits of the cholera enterotoxin (choleragen).

Authors:  R A Finkelstein; M Boesman; S H Neoh; M K LaRue; R Delaney
Journal:  J Immunol       Date:  1974-07       Impact factor: 5.422

7.  Tissue receptor for cholera exotoxin: postulated structure from studies with GM1 ganglioside and related glycolipids.

Authors:  J Holmgren; I Lönnroth; L Svennerholm
Journal:  Infect Immun       Date:  1973-08       Impact factor: 3.441

8.  Radioimmunoassay for the antigenic determinants of cholera toxin and its components.

Authors:  K E Hejtmancik; J W Peterson; D E Markel; A Kurosky
Journal:  Infect Immun       Date:  1977-09       Impact factor: 3.441

9.  Mechanism of action of choleragen. Evidence for ADP-ribosyltransferase activity with arginine as an acceptor.

Authors:  J Moss; M Vaughan
Journal:  J Biol Chem       Date:  1977-04-10       Impact factor: 5.157

10.  Pathogenesis of experimental cholera. Preparation and isolation of choleragen and choleragenoid.

Authors:  R A Finkelstein; J J LoSpalluto
Journal:  J Exp Med       Date:  1969-07-01       Impact factor: 14.307

View more
  16 in total

1.  Genetic construction, expression, and melanoma-selective cytotoxicity of a diphtheria toxin-related alpha-melanocyte-stimulating hormone fusion protein.

Authors:  J R Murphy; W Bishai; M Borowski; A Miyanohara; J Boyd; S Nagle
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

2.  Cloning and expression in Escherichia coli of three fragments of diphtheria toxin truncated within fragment B.

Authors:  W R Bishai; A Miyanohara; J R Murphy
Journal:  J Bacteriol       Date:  1987-04       Impact factor: 3.490

3.  Monoclonal antibodies: technology and application to gram-negative infections.

Authors:  L S Young
Journal:  Infection       Date:  1985       Impact factor: 3.553

Review 4.  Monoclonal antibodies: technology and application to gram-negative infections.

Authors:  L S Young
Journal:  Infection       Date:  1984 Jul-Aug       Impact factor: 3.553

5.  Comparative immunogenicities of Vi polysaccharide-protein conjugates composed of cholera toxin or its B subunit as a carrier bound to high- or lower-molecular-weight Vi.

Authors:  S C Szu; X R Li; R Schneerson; J H Vickers; D Bryla; J B Robbins
Journal:  Infect Immun       Date:  1989-12       Impact factor: 3.441

6.  Characterization of monoclonal antibodies against Shiga-like toxin from Escherichia coli.

Authors:  N A Strockbine; L R Marques; R K Holmes; A D O'Brien
Journal:  Infect Immun       Date:  1985-12       Impact factor: 3.441

7.  Enhanced complement-mediated lysis of type III paroxysmal nocturnal hemoglobinuria erythrocytes involves increased C9 binding and polymerization.

Authors:  V W Hu; A Nicholson-Weller
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

8.  Characterization of monoclonal antibodies that react with unique and cross-reacting determinants of cholera enterotoxin and its subunits.

Authors:  R K Holmes; E M Twiddy
Journal:  Infect Immun       Date:  1983-12       Impact factor: 3.441

9.  Production and characterization of monoclonal antibodies to tetanus toxin.

Authors:  A J Sheppard; D Cussell; M Hughes
Journal:  Infect Immun       Date:  1984-02       Impact factor: 3.441

10.  Immunity to heat-labile enterotoxins of porcine and human Escherichia coli strains achieved with synthetic cholera toxin peptides.

Authors:  C O Jacob; R Arnon; R A Finkelstein
Journal:  Infect Immun       Date:  1986-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.